NCT00940641

Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

A Phase 1, Open, Two Period, Single-Centre, Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) After Intravenous and 14C-labelled Oral Administration of AZD7325 to Healthy Male Volunteers

• Status: Suspended
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: Male
• Age: 35 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of AZD7325 after intravenous and 14C labeled oral dose

Conditions

• Absorption
• Distribution
• Metabolism
• Excretion

Interventions

Type	Name	Description
DRUG	AZD7325	IV Dose
DRUG	AZD7325	oral dose

Timeline

• Start date: 2009-08-01
• Primary completion: 2009-10-01
• Completion: 2009-10-01
• First posted: 2009-07-16
• Last updated: 2011-01-24

Locations

1 site across 1 country: United Kingdom